Clinical Trials

Exelixis is currently conducting a comprehensive clinical development program for cabozantinib in prostate cancer. Several Exelixis-sponsored trials in other cancer indications have completed enrollment and continue to generate data that will inform future development in other types of cancer. Additional clinical trials are being conducted under a Cooperative Research and Development Agreement with the National Institute’s of Health Cancer Therapy Evaluation Program and through our Investigator Sponsored Trial program.